18th International Forum on Mood and Anxiety Disorders

Vienna (Austria)
04 – 06 July 2019

Final Programme

In Collaboration with
ISAD
International Society for Affective Disorders

IFMAD

10 CME Credits Granted

Chairmen
Siegfried Kasper (Austria)
Stuart A. Montgomery (UK)
Allan H. Young (UK)
Eduard Vieta (Spain)

www.ifmad.org/2019
Dear Colleagues, dear Friends,

We are delighted to invite you to the 18th International Forum on Mood and Anxiety Disorders that will be held in July in Vienna.

IFMAD has a long and successful tradition of inviting international expert speakers on subjects which provide new insights in treatment of various psychiatric disorders. The meeting always takes place in a collegiate setting which allows for an open interaction between speakers, other experts present and the registrants both in the meeting room and in the intervals.

This year we expect a lively discussion on treatment resistant depression with new findings on rapid response within a day in TRD. The latest findings on the genetic basis of TRD will open the way to the use of personalized treatment of depression to reduce the chance of resistance developing. There will be overviews of the contribution of inflammation to mood and anxiety disorders and also the link between nutrition and psychiatry. Updates on new antipsychotics in schizophrenia and on the treatment of negative and depressive symptoms in schizophrenia will be presented. New studies on bipolar disorders have helped clarify the issues of treatment of bipolar depression and the associated cognitive impairment. An update on the risks of valproate will question its widespread use. A major current concern, which will be addressed in the meeting, is the apparent overuse of valproate in women of child bearing age. There will be sessions on anxiety disorders and a focus on long-term treatment and on comorbiditiy with alcohol dependence. We look forward to updates on the application of digital technology in psychiatry and the need for and use of rapid treatments for suicidality.

We look forward to seeing you all in Vienna for IFMAD 2019, to building strong professional contacts an expanding international network, to welcoming new participants and meeting our old friends, and discussing together the most important issues in this area of medicine!

A warm welcome from IFMAD chairmen!

Siegfried Kasper  
Stuart Montgomery  
Eduard Vieta  
Allan Young
ACKNOWLEDGEMENTS

For their contribution in supporting the poster presenters

For their contribution to the Scientific Programme

For their contribution to the Congress

VIENNA CONVENTION BUREAU

SCIENTIFIC ADVISERS

D. Baldwin (United Kingdom), B. Bandelow (Germany), M. Bauer (Germany), T. Dinan (Ireland), E. Eriksson (Sweden), N. Fineberg (United Kingdom), S. Kennedy (Canada), D. Lecic Tosevski (Serbia), A.A. Mathé (Sweden), H.J. Möller (Germany), S. Pallanti (Italy), J. Raboch (Czech Republic), Z. Rihmer (Hungary), A. Serretti (Italy), D.J. Stein (South Africa), T. Svensson (Sweden), D. Winkler (Austria), S. Yamawaki (Japan), J. Zohar (Israel)
## SCIENTIFIC PROGRAMME - Thursday, 04 July 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15h00 - 18h20</td>
<td><strong>SCIENTIFIC SESSION</strong> – Chairs: S. KASPER – E. VIETA</td>
<td></td>
</tr>
<tr>
<td>15h00 - 15h40</td>
<td><strong>SE. 01</strong> Personalised treatment of TRD in practice</td>
<td>Alexander Kautzky (Austria)</td>
</tr>
<tr>
<td>15h40 - 16h20</td>
<td><strong>SE. 02</strong> Nutritional psychiatry: focus on mood disorders</td>
<td>Timothy Dinan (Ireland)</td>
</tr>
<tr>
<td>16h20 - 17h00</td>
<td><strong>SE. 03</strong> Treating cognitive dysfunction in mood disorders</td>
<td>Eduard Vieta (Spain)</td>
</tr>
<tr>
<td>17h00 - 17h40</td>
<td><strong>SE. 04</strong> Advances in technology and digital psychiatry</td>
<td>Diego Hidalgo-Mazzei (Spain)</td>
</tr>
<tr>
<td>17h40 - 18h20</td>
<td><strong>On-line Survey</strong></td>
<td>Stuart Montgomery (United Kingdom)</td>
</tr>
<tr>
<td>18h30</td>
<td><strong>OPENING RECEPTION</strong></td>
<td></td>
</tr>
</tbody>
</table>

## SCIENTIFIC PROGRAMME - Friday, 05 July 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09h00 - 11h00</td>
<td><strong>SCIENTIFIC SESSION</strong> – Chairs: T. DINAN - N. FINEBERG</td>
<td></td>
</tr>
<tr>
<td>09h00 - 09h40</td>
<td><strong>SE. 05</strong> Recent regulatory guidance about certain mood-stabilising medicines in women of child-bearing potential: are some prescriptions worth the risk?</td>
<td>David Baldwin (United Kingdom)</td>
</tr>
<tr>
<td>09h40 - 10h20</td>
<td><strong>SE. 06</strong> Therapeutic implications of including hypochondriasis in the ICD-11 Obsessive-Compulsive or Related Disorders (OCRDs)</td>
<td>Naomi Fineberg (United Kingdom)</td>
</tr>
<tr>
<td>10h20 - 11h00</td>
<td><strong>SE. 07</strong> Enduring effect of psychotherapy vs medication in anxiety disorders</td>
<td>Borwin Bandelow (Germany)</td>
</tr>
<tr>
<td>11h00 - 11h30</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
</tr>
<tr>
<td>11h30 - 12h30</td>
<td><strong>SPONSORED SESSION</strong></td>
<td></td>
</tr>
<tr>
<td>12h30 - 13h30</td>
<td><strong>LUNCH</strong></td>
<td></td>
</tr>
</tbody>
</table>
13h30 – 15h30  SCIENTIFIC SESSION – Chairs: B. BANDELOW - A. YOUNG

13h30 - 14h10  SE. 08 New findings on lithium
Markus Dold (Austria)

14h10 - 14h50  SE. 09 Can we restore altered biological pathways in TRD starting from genetic findings?
Chiara Fabbri (Italy)

14h50 - 15h30  SE. 10 Treatment of depressive and negative symptoms of schizophrenia
Istvan Bitter (Hungary)

15h30 - 16h00  COFFEE BREAK

16h00 – 18h00  SCIENTIFIC SESSION – Chairs: A. SERRETTI - A. YOUNG

16h00 - 16h40  SE. 11 The role of anxiety in Baclofen treatment for alcohol dependence
Julia Sinclair (United Kingdom)

16h40 - 17h20  SE. 12 Rapid Acting treatment in depression
Siegfried Kasper (Austria)

17h20 - 18h00  SE. 13 Psychopharmacological approaches to Bipolar Depression
Allan Young (United Kingdom)

18h00 - 18h30  KEYNOTE LECTURE – Chair: I. BITTER

18h00 - 18h30  Transcranial magnetic stimulation
Stefano Pallanti (Italy)

SCIENTIFIC PROGRAMME - Saturday, 06 July 2019

08h30 - 09h30  STROLLING POSTER SESSION AND COFFEE BREAK
Chairs: S. MONTGOMERY - S. KASPER - A. YOUNG – S. PALLANTI

09h30 – 11h20  SCIENTIFIC SESSION – Chairs: C. FABBRI - S. MONTGOMERY

09h30 - 10h10  SE. 14 New antipsychotics in the treatment of depression
Alessandro Serretti (Italy)

10h10 - 10h40  SE. 15 Inflammation in Affective Disorders
Allan Young (United Kingdom)

10h40 - 11h20  SE. 16 Genetic testing in psychiatry : what clinicians need to know
Chiara Fabbri (Italy)

11h20 - 12h15  CLOSING REMARKS - POSTER AWARDS AND FAREWELL COFFEE
Industry Sponsored Lecture – Friday, 05 July 2019

DISCLAIMER: THE FOLLOWING LECTURE IS ORGANISED BY INDUSTRY. YOU CANNOT CLAIM CME CREDITS FOR ATTENDING THIS SESSION

11h30 - 12h30 SPONSORED SESSION

‘How to manage patients with treatment resistant depression: could it also be ADHD?’
Toni Ramos (Spain)

This lecture is organised and funded by Shire, now part of Takeda (and is intended for Healthcare Professionals only).
Equipment for computerized Power Point presentation is provided during the scientific sessions. Power Point presentations, CD-Rom or USB keys can be viewed and tested prior to presentation at the Speakers’ Corner and must be handed over to the room technicians at least forty minutes before the beginning of the sessions and collected directly by the speakers immediately after. It is essential for the smooth running of the sessions that all Speakers hand in their presentation in due time.

The IFMAD Workshop has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 10 European CME credits (ECMEC®s). To obtain your certificate please log in with your personal log-in credentials sent by mail on the website http://ifmad.org/, and complete the questionnaire. Credits' certificates will be available from July 12th, 2019 to July 20th, 2019. After this date they will not be available anymore.

The certificate of attendance will be downloadable from the website www.ifmad.org using your personal credentials sent by e-mail, starting from July 12th, 2019.

The participant's name badge are provided at the registration desk. All participants are requested to wear the badge throughout the congress. Only badge holders are admitted to the appropriate sessions and Opening Reception.

The official language of the Congress is English. No simultaneous translation is provided. The Congress organizers cannot accept liability for personal injuries sustained, or for loss or damage to.

The secretariat desk opens on Thursday, 04 July 2019 and stays open all through the Congress.

All delegates are cordially invited to attend the Opening Reception which is held on Thursday, 04 July at 18.30 at the Imperial Riding School Hotel.
P.01 The basis of Ketamine action and its role on the treatment of Major Depressive Disorder  
Hugo Afonso1; Vera Froes1; Ivan Varela1; Sergio Esteves1; Miguel Carneiro1; Glaucia Lima1  
1Centro Hospitalar de Barreiro Montijo, Barreiro, Portugal

P.02 Practice of maintenance electroconvulsive therapy  
Jakub Albrecht1; Tadeas Mares1; Jozef Buday1; Gabriela Podgorna1; Jiri Raboch1; Martin Anders1  
1Department of Psychiatry First Faculty of Medicine Charles University and General University Hospital, Prague, Czech Republic

P.03 The Impact of Suicidality on Major Depressive Disorder - Results from the European Group for the Study of Resistant Depression  
Lucie Bartova1; Markus Dold1; Gernot Fugger1; Alexander Kautzky1; Daniel Souery2,3; Julien Mendlewicz2; George N. Papadimitriou4; Dimitris Diakos4; Panagiotis Ferentinos5; Stefano Porcelli6; Alessandro Serretti6; Joseph Zohar7; Stuart Montgomery8; Siegfried Kasper1  
1Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; 2School of Medicine, Free University of Brussels, Brussels, Belgium; 3Psy Pluriel - European Centre of Psychological Medicine, Brussels, Belgium; 4First Department of Psychiatry, Medical School, National and Kapodistrian University of Athens, Eginion Hospital, Athens, Greece; 5Second Department of Psychiatry, Medical School, National and Kapodistrian University of Athens, Attikon General Hospital, Athens, Greece; 6Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy; 7Psychiatric Division, Chaim Sheba Medical Center, Tel Hashomer, Israel; 8Imperial College, University of London, London, United Kingdom

P.04 Spadin and shortened spadin analogs as efficient new antidepressants in mouse models of post-stroke depression  
Marc Borsotto1; Mariel Pietri1; Alaeddine Djillani1; Jean Mazella1; Catherine Heurteaux1  
1Centre National de la Recherche Scientifique, Institut De Pharmacologie Moléculaire et Cellulaire, UMR7275, Valbonne, France

P.05 Comparison of depression, anxiety, and suicide ideation in transgender individuals based on their parents’ reaction  
Jinhyuk Choi1  
1Bongseng memorial hospital, Busan, South Korea

P.06 Bipolar Disorder – Is gender important?  
Ana Beatriz Cordeiro de Medeiros1; Cátia Fernandes Santos1; Magda Veiga Pereira1  
1Serviço de Psiquiatria e Saúde Mental do Hospital Garcia de Orta, Almada, Portugal
P.07 Seasonal variation of benzodiazepine utilization among the Croatian population
Marija Delaš Aždajić1,3; Stjepan Aždajić1; Robert Likic2,3; Danijela Štimac Grbić3,4
1Sestre Milosrdnice University Hospital Center, Zagreb, Croatia; 2University Hospital Centre Zagreb, Zagreb, Croatia; 3School of Medicine, University of Zagreb, Zagreb, Croatia; 4Croatian Institute of Public Health, Zagreb, Croatia

P.08 Pharmacological management of acute mania: a 2-year retrospective study of prescription patterns in a portuguese acute psychiatric unit
Cátia Fernandes Santos1; Ana Beatriz Medeiros1; Filipa Senos Moutinho1
1Department of Psychiatry and Mental Health, Hospital Garcia de Orta, Almada, Portugal

P.09 Cyberchondria as an emerging trans-diagnostic digital compulsive syndrome: An updated systematic review and clinical case report
Matteo Vismara1,2; Eduardo Cinosi1,3; Bernardo Dell’Osso2; Giovanni Martinotti3,4; Naomi A Fineberg1,3
1Hertfordshire Partnership University NHS Foundation Trust, Rosanne House, Welwyn Garden City, Hertfordshire, United Kingdom; 2University of Milan, Department of Mental Health, Department of Biomedical and Clinical Sciences Luigi Sacco, Milan, Italy; 3University of Hertfordshire, Hatfield, United Kingdom; 4University G.d’Annunzio University, Department of Neuroscience, Imaging, Clinical Sciences, Chieti-Pescara, Italy

P.10 The study of the clinical and psychological characteristics of patients with anxious neurotic disorders in the course of analytical-cathartic therapy.
Evgenii Ilchenko1
1St. Petersburg "Hospital named after P.P. Kashchenko", Saint Petersburg, Russian Federation

P.11 Pain behavior: new application of dire scale in patients with chronic pain syndromes
Olena Khaustova1
1Bogomolets National Medical University, Kyiv, Ukraine

P.12 Oriental herbal medicine for insomnia in elderly with hypertension: a systematic review and meta-analysis
SangHo Kim1
1Department of Neuropsychiatry of Korean Medicine, Pohang Korean Medicine Hospital Affiliated to Daegu Haany University, Pohang, South Korea

P.13 Rapid augmentation of antipsychotic drugs by sodium nitroprusside (SNP). Behavioral assessment and effect on brain dopaminergic transmission in rats
Joep Titulaer1,2; Anna Malmerfelt2; Monica Marcus2; Åsa Konradsson Geuken1,2; Alessia Perrone3; Giesbert Alken3; John Lowry4; Torgny Svensson2
1Uppsala University, Uppsala, Sweden; 2Karolinska Institutet, Stockholm, Sweden; 3BDD Drug Development GmbH, Berlin, Germany; 4National University of Ireland Maynooth, Maynooth, Ireland
P.14 Association between cognitive functions and suicidal ideation in patients with mood disorder
Suyeon Lee1; Woojae Myung1; Kichang Kim1; Sunghee Oh1; Nayoung Cho1; Yun seong Park1; Taewon Chung1; Hyun A Ryoo1; Tae Hyon Ha1
1Department of Psychiatry, Seoul National University Bundang Hospital, Seongnam, South Korea

P.15 Personalized psychotherapy system for depressive disorders, taking into account the prognosis factors of their course
Natalia Maruta1; Viktoriya Fedchenko1
1"Institute of neurology, psychiatry and narcology of NAMS of Ukraine" SI, Kharkiv, Ukraine

P.16 Peculiarities of anxiety in the structure of mental health disorders of different genesis
Nataliya Maruta1; Tamara Panko1; Iryna Yavdak1; Galina Kalenskaya1; Oksana Maruta1
1"Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine" SI, Kharkiv, Ukraine

P.17 Menière’s disease – a psychosomatic disorder?
Ana Beatriz Medeiros1; Filipe Correia2; Luís Castelhano2; Pedro Cavilhas2
1Serviço de Psiquiatria e Saúde Mental do Hospital Garcia de Orta, Almada, Portugal; 2Serviço de Neurologia do Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal

P.18 Is there abnormal functional connectivity between the cerebellum and the cerebrum networks in unmedicated patients with obsessive-compulsive disorder?
Keitaro Murayama1; Tomohiro Nakao1; Tomiyama Hirofumi1; Hasuzawa Suguru1; Tsuruta Sae2; Ohno Aikana2
1Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; 2Department of Clinical Psychology Practice, Graduate School of Human-Environment Studies, Kyushu University, Fukuoka, Japan

P.19 Exposure to Ambient Fine Particles and Depressive Symptoms in Alzheimer Disease: CREDOS (Clinical Research Center for Dementia of South Korea) Study
Woojae Myung1; Hyewon Lee1,2; Hyeong-gwon An3
1Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, South Korea; 2Institute of Health and Environment, Seoul National University, Seoul, South Korea; 3Department of Psychiatry, CHA Bundang Medical Center, CHA University, Seongnam, South Korea

P.20 Mobile app for the add-on treatment of generalized anxiety disorder and anxiety in mild to moderate depressive disorder – an assessment of need of patients and health care professionals
Daniel Neto1,2; Carla Spinola3; Ana Ribeiro Moreira3; Teresa Castelo Branco2; Helena Sofia Pinto4; Joaquim Gago2,5
1Casa de Saúde São João de Deus,, Funchal, Portugal; 2Clínica Grow Space, Lisboa, Portugal; 3Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal; 4Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal; 5Nova Medical School, Lisboa, Portugal
P.21 The Effects of a Mobile Application using the MBSR technique on symptom relief of outpatients with panic disorder: A pilot study
Sunyoung Park¹; Jungeun You²,³; Jungeun Song¹
¹Department of Psychiatry, National Health Insurance Service Ilsan Hospital, Goyang, South Korea; ²Department of Psychology, Seoul National University, Seoul, South Korea; ³MABO, Seoul, South Korea

P.22 Clinical Implication of Agoraphobia in the Patients with Panic Disorder
Jin Shin¹; Jun Jeon Hong¹
¹Department of Psychiatry, Konkuk University Medical Center, Seoul, South Korea

P.23 Understanding the essence of Mood Disorders through the eyes of poetry
Gulbahar Sidhu¹
¹Doaba Hospital, Jalandhar, India

P.24 Lithium or valproate in Bipolar Disorder? A 3-Year Prospective Cohort Study
Carla Spínola¹; Daniel Neto²; Leonor Santana¹; Filipe De Oliveira Azevedo¹; Joaquim Gago¹,³
¹Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal; ²Casa de Saúde São João de Deus, Funchal, Portugal; ³Nova Medical School, Lisboa, Portugal

P.25 Unique Pharmacology and Clinical Evidence Supporting the Antidepressant Therapeutic Potential of Lumateperone
Joep Titulaer¹,²; Robert Davies³; Sophie Dutheil³; Joseph Hendricks³; Lei Zhang³; Lawrence Wennogle³; Andrew Satlin³; Monica Marcus³; Sharon Mates³; Kim Vanover³; Gretchen Snyder³; Torgny Svensson²
¹Uppsala University, Uppsala, Sweden; ²Karolinska Institutet, Stockholm, Sweden; ³Intra Cellular Therapies, New York, USA